tetano
Editor, Senior Moderator
JCI Insight
. 2024 Dec 3:e182704.
doi: 10.1172/jci.insight.182704. Online ahead of print. Repurposing of lonafarnib as a treatment for SARS-CoV-2 infection
Mohsin Khan[SUP] 1 [/SUP], Parker Irvin[SUP] 1 [/SUP], Seung Bum Park[SUP] 1 [/SUP], Hannah M Ivester[SUP] 2 [/SUP], Inna Ricardo-Lax[SUP] 3 [/SUP], Madeleine Leek[SUP] 1 [/SUP], Ailis Grieshaber[SUP] 1 [/SUP], Eun Sun Jang[SUP] 1 [/SUP], Sheryl L Coutermarsh-Ott[SUP] 2 [/SUP], Qi Zhang[SUP] 4 [/SUP], Nunziata Maio[SUP] 5 [/SUP], Jian-Kang Jiang[SUP] 4 [/SUP], Bing Li[SUP] 4 [/SUP], Wenwei Huang[SUP] 4 [/SUP], Amy Q Wang[SUP] 4 [/SUP], Xin Xu[SUP] 4 [/SUP], Zongyi Hu[SUP] 1 [/SUP], Wei Zheng[SUP] 4 [/SUP], Yihong Ye[SUP] 6 [/SUP], Tracey Rouault[SUP] 5 [/SUP], Charles M Rice[SUP] 3 [/SUP], Irving C Allen[SUP] 2 [/SUP], T Jake Liang[SUP] 1 [/SUP]
Affiliations
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes Coronavirus disease 2019 (COVID-19), has emerged as a global pandemic pathogen with high mortality. While treatments have been developed to reduce morbidity and mortality of COVID-19, more antivirals with broad-spectrum activities are still needed. Here we identified lonafarnib (LNF), a Food and Drug Administration (FDA)-approved drug inhibitor of cellular farnesyltransferase (FTase), as an effective anti-SARS-CoV-2 agent. LNF inhibited SARS-CoV-2 infection and acted synergistically with known anti-SARS antivirals. LNF was equally active against diverse SARS-CoV-2 variants. Mechanistic studies suggested that LNF targeted multiple steps of viral life cycle. Using other structurally diverse FTase inhibitors and LNF-resistant FTase mutant, we demonstrated a key role of FTase in SARS-CoV-2 life cycle. To demonstrate in vivo efficacy, we infected SARS-CoV-2 susceptible humanized mice expressing human angiotensin-converting enzyme 2 (ACE2) and treated them with LNF. LNF at clinically relevant dose suppressed viral titer in the respiratory tract and improved pulmonary pathology and clinical parameters. Our study demonstrated that LNF, an approved oral drug with excellent human safety data, is a promising antiviral against SARS-CoV-2 that warrants further clinical assessment for treatment of COVID-19 and potentially other viral infections.
Keywords: COVID-19; Drug screens; Drug therapy; Molecular biology; Virology.
. 2024 Dec 3:e182704.
doi: 10.1172/jci.insight.182704. Online ahead of print. Repurposing of lonafarnib as a treatment for SARS-CoV-2 infection
Mohsin Khan[SUP] 1 [/SUP], Parker Irvin[SUP] 1 [/SUP], Seung Bum Park[SUP] 1 [/SUP], Hannah M Ivester[SUP] 2 [/SUP], Inna Ricardo-Lax[SUP] 3 [/SUP], Madeleine Leek[SUP] 1 [/SUP], Ailis Grieshaber[SUP] 1 [/SUP], Eun Sun Jang[SUP] 1 [/SUP], Sheryl L Coutermarsh-Ott[SUP] 2 [/SUP], Qi Zhang[SUP] 4 [/SUP], Nunziata Maio[SUP] 5 [/SUP], Jian-Kang Jiang[SUP] 4 [/SUP], Bing Li[SUP] 4 [/SUP], Wenwei Huang[SUP] 4 [/SUP], Amy Q Wang[SUP] 4 [/SUP], Xin Xu[SUP] 4 [/SUP], Zongyi Hu[SUP] 1 [/SUP], Wei Zheng[SUP] 4 [/SUP], Yihong Ye[SUP] 6 [/SUP], Tracey Rouault[SUP] 5 [/SUP], Charles M Rice[SUP] 3 [/SUP], Irving C Allen[SUP] 2 [/SUP], T Jake Liang[SUP] 1 [/SUP]
Affiliations
- PMID: 39625789
- DOI: 10.1172/jci.insight.182704
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes Coronavirus disease 2019 (COVID-19), has emerged as a global pandemic pathogen with high mortality. While treatments have been developed to reduce morbidity and mortality of COVID-19, more antivirals with broad-spectrum activities are still needed. Here we identified lonafarnib (LNF), a Food and Drug Administration (FDA)-approved drug inhibitor of cellular farnesyltransferase (FTase), as an effective anti-SARS-CoV-2 agent. LNF inhibited SARS-CoV-2 infection and acted synergistically with known anti-SARS antivirals. LNF was equally active against diverse SARS-CoV-2 variants. Mechanistic studies suggested that LNF targeted multiple steps of viral life cycle. Using other structurally diverse FTase inhibitors and LNF-resistant FTase mutant, we demonstrated a key role of FTase in SARS-CoV-2 life cycle. To demonstrate in vivo efficacy, we infected SARS-CoV-2 susceptible humanized mice expressing human angiotensin-converting enzyme 2 (ACE2) and treated them with LNF. LNF at clinically relevant dose suppressed viral titer in the respiratory tract and improved pulmonary pathology and clinical parameters. Our study demonstrated that LNF, an approved oral drug with excellent human safety data, is a promising antiviral against SARS-CoV-2 that warrants further clinical assessment for treatment of COVID-19 and potentially other viral infections.
Keywords: COVID-19; Drug screens; Drug therapy; Molecular biology; Virology.